Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24
Open Access
- 1 May 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (9) , 3377-3384
Abstract
Purpose: The purpose of this work was to test the suitability of the HM1.24 antigen as a CTL target for immunotherapy of patients with multiple myeloma. Experimental Design: Antigen-specific T cells were generated from patients with multiple myeloma using stimulation with protein-pulsed dendritic cells and tested in ELISPOT and CTL assays. Results: HM1.24-primed T cells responded selectively to HM1.24-loaded autologous peripheral blood mononuclear cells (PBMC) in an IFN-γ ELISPOT assay (median, 342; range, 198-495 IFN-γ–producing cells/105 cf. unloaded PBMC median, 98; range, 7-137; P < 0.05, n = 5) and also to autologous malignant plasma cells (MPC; median, 227; range, 153-335; P < 0.05 when compared with the response to allogeneic MPC median, 57; range, 22-158; n = 5). HM1.24-primed T cells lysed autologous MPC (at 20:1 E/T ratio: median, 48% specific killing; range, 23-88%; at 10:1 E/T ratio: median, 43%; range, 15-80%; n = 12) but not allogeneic MPC. Lysis of autologous MPC was inhibited by anti–MHC class I but not anti–MHC class II antibodies and was blocked by Concanamycin A. Lysis of autologous MPC was blocked by competition with autologous HM1.24-transfected dendritic cells (10:1 ratio with autologous MPC). Unmanipulated, or control plasmid–transfected dendritic cells had no effect on lysis of autologous MPC. Conclusion: Our results indicate that HM1.24 is a promising target for immunotherapy of multiple myeloma.Keywords
This publication has 28 references indexed in Scilit:
- Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytesBlood, 2003
- Current Developments in Cancer Vaccines and Cellular ImmunotherapyJournal of Clinical Oncology, 2003
- Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNABlood, 2003
- T cells in myelomaHematological Oncology, 2003
- Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myelomaBlood, 2002
- Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma CellsBiochemical and Biophysical Research Communications, 1999
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.Journal of Experimental Medicine, 1996
- Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.Journal of Experimental Medicine, 1996
- ADP ribosyl cyclase activity of a novel bone marrow stromal cell surface molecule, BST‐1FEBS Letters, 1994